Wells Fargo becomes bullish on this biotech company

  • 📰 CNBC
  • ⏱ Reading Time:
  • 23 sec. here
  • 10 min. at publisher
  • 📊 Quality Score:
  • News: 40%
  • Publisher: 72%

Health Care Industry Noticias

Neurocrine Biosciences Inc,Wells Fargo & Co,Stock Markets

Wells Fargo believes the company's hyperplasia and depression treatments could each become over $1 billion opportunities.

Neurocrine Biosciences ' drug pipeline is turning a corner and the company will be "knocking on the doors of the large-cap club" soon, according to Wells Fargo. Analyst Mohit Bansal upgraded shares to overweight from equal weight, and raised his price target to $170 from $140, suggesting around 21% upside potential from Tuesday's close. Bansal forecasts the company's congenital adrenal hyperplasia treatment, crinecerfont, will achieve $1.

"We think Crinecerfont is underappreciated as the Street is only giving credit for $500-$700M peak opportunity." Elsewhere in the company's pipeline, Neurocrine's depression drug NBI-1065845, developed in conjunction with Japanese pharmaceutical company Takeda, showed positive results during a phase II trial. Bansal said this drug could open "a whole new chapter" of a $1.2 billion peak sales opoprtunity.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 12. in ES
 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.

España Últimas Noticias, España Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

S&P 500 target raised to 5500+ at Wells Fargo on strong earnings growthS&P 500 target raised to 5500+ at Wells Fargo on strong earnings growth
Fuente: Investingcom - 🏆 450. / 53 Leer más »